DPI Research: Global Epilepsy Drug Market to Reach USD 5.5 Billion by 2021

Press Release (ePRNews.com) - VASANT KUNJ, India - Mar 21, 2017 - Epilepsy Drugs Market is likely to reach nearly USD 5.5 Billion by the year end of 2021.

Browse full table of content at

http://www.dpiresearch.com/report-details.php?P_ID=97

Market growth can be attributed to factors such as rising incidence of neurological disorders, growing disease awareness, introduction of novel antiepileptic drugs (AEDs), strong government support and initiatives. Moreover, increasing R&D investment and launch of extended-release formulations are further expected to fuel the market growth. However, high cost of patented drugs, concerns over decreasing healthcare costs as part of government austerity measures, particularly in Europe and low accessibility to antiepileptic drugs in low and middle income countries, are likely to restrict the market growth.

Vimpat is the undisputed leading drug of Global Epilepsy Drugs Market. It has a market share of nearly 22% in 2016 and is expected that Vimpat will gain its momentum till the forecasting period. Keppra was the second highest market share taker with more than 19% share in 2016 but the prospect of this drug will change due to the patent expiration in 2018 and its share decline to XX% by 2021. It is expected that Lamictal will be second leading drug with nearly XX% share by 2021. Onfi hold the third highest share of the Epilepsy Drugs market, being followed by Depakine by the year end of 2021.

The research report titled “Epilepsy Drugs Market: Global Demand, Growth Potential & Opportunity Outlook 2021” examines the market, competitive landscape and trends of the Global Epilepsy Drug Market. This report analyzes market data and provides a better understanding of Epilepsy Drugs sales value and demand in the Global Market. Market outlook in value terms for the forecasted period for Epilepsy Drugs Market has been detailed in the report. Key trends in terms of collaborations, partnerships and licensing agreements are analysed with details. The report also explores detailed description of growth drivers and inhibitors of the Global Epilpesy Drugs Market.

The report concludes with the profiles of major players in the Epilepsy Drugs Market such as UCB, EISAI, Pfizer, Sanofi and Lundbeck. The major market players are evaluated on various parameters such as company overview and latest development and trends in the Epilepsy Drugs Market

Key Topics Covered in the Report

•Worldwide Epilepsy Drugs Market Analysis (2013 – 2021)

•Worldwide Epilepsy Drugs Market Share (2013 – 2021)

•Worldwide Epilepsy Drugs Brand Market Performance (2013 – 2021)

•Epilepsy Drugs Market – Major Deal Types

•Key Companies Analysis

•Key Drivers and Inhibitors of the Epilepsy Drugs Market

Key Epilepsy Drugs Covered in the Report are as follows:

1.Vimpat(Lacosamide)

2.Keppra(Levetiracetam)

3.Briviact(Brivaracetam)

4.Lamictal(Lamotrigine)

5.Neurontin (Gabapentin)

6.Depakine (Sodium Valproate)

7.Sabril (Vigabatrin)

8.Onfi(Clobazam)

9.Fycompa(Perampanel)

10.Inovelon/Banzel(Rufinamide)

11.Zonegran (Zonisamide)

12.Zebinix (Eslicarbazepine Acetate)

Key Companies Covered in the Report are as follows:

1.UCB

2.EISAI

3.Pfizer

4.Sanofi

5.Lundbeck

For More Information Visit

http://www.dpiresearch.com/

Contact Info:

Name: Maria Rai,Sales Manager

Email: sales@dpiresearch.com

Organization: DPI Research

Phone: + 91 728-994-9987


****
This Free PR posting shall be removed from listing sooner. If you are authorized representative for this PR and want permanent listing, you can upgrade to Premium PR listing. Contact us at info@eprnews.com for other personalized offers.
****

You may also like this  

CATEGORIES : Healthcare
DISCLAIMER : If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/services/business mentioned and hereby disclaims any content contained in this press release.

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login